Aptose Biosciences Inc.

Informe acción OTCPK:APTO.F

Capitalización de mercado: US$4.3m

Aptose Biosciences Dirección

Dirección controles de criterios 3/4

El CEO de Aptose Biosciences es William Rice , nombrado en Oct 2013, tiene una permanencia de 12.58 años. compensación anual total es $1.08M, compuesta por 62.8% salario y 37.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.18% de las acciones de la empresa, por valor de $7.56K. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 12.6 años, respectivamente.

Información clave

William Rice

Chief Executive Officer (CEO)

US$1.1m

Compensación total

Porcentaje del salario del CEO62.81%
Permanencia del CEO12.6yrs
Participación del CEO0.2%
Permanencia media de la dirección6.3yrs
Promedio de permanencia en la Junta Directiva12.6yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Aug 01

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q2 earnings results on Monday, August 1st, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 6 upward revisions and 0 downward.
Seeking Alpha • Jul 19

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023. There is a sizable market opportunity for drugs to address patients with hematological cancers who've progressed on other therapies, but the odds and timelines are long. I believe fair value for Aptose is around $4 today, but upside is tied to future positive clinical developments and there's not much room for stumbles or setbacks. It wouldn't be fair to say that there's been no clinical progress at Aptose Biosciences (APTO) since my last update, but there certainly hasn't been enough to really sway investor sentiment, particularly in light of a more risk-averse biotech market. Aptose has two credible hematological oncology products in the pipeline, but there is a still lot of de-risking needed for both programs. I do believe that the market is still heavily discounting the odds of clinical success here, but given the history of oncology drug development, and Aptose's own shaky clinical progress, that's not exactly unfair. I can still see a path toward a substantially higher fair value, but the reality is that investors are likely going to need to wait a year or more for sentiment-moving data. '239 Is Worth Further Exploration From five complete responses and one partial response back at the December 2021 ASH update, Aptose has seen two more complete responses in its HM43239 (or '239) program in relapsed or refractory AML, bringing the total to seven complete responses and one partial response among a 80mg, 120mg, and 160mg dosing group that has treated at least 41 patients as off the last cut-off (early June, ahead of the EHA meeting). Thus far the drug has shown encouraging safety/tolerability, with only one dose-limiting toxicity reported so far (muscle weakness in a patient getting a 200mg dose). While the response rates aren't eye-popping at this point, it's worth remembering that these are not the healthiest patients, as they've already seen drug progression after prior treatments. Based on the early clinical results, management is moving forward with further dose exploration at 80mg, 120mg, and 160mg (the 80mg segment has been completed, with the 120mg and 160mg cohorts about half-complete as of early June) and then two expansion studies. One expansion study will use 120mg (with 80mg and 160mg as bracketing dosages) of '293 as a single-agent therapy in FLT-3 mutated and unmutated AML, while the other will be a combination study with venetoclax (Venclexta, marketed by AbbVie (ABBV) and Roche (RHHBY)). The single-agent study should start later this year, with the combo study slated for the first half of 2023. Should the results of these studies merit it, registrational studies would then start - presumably in 2024 for the single-agent study. It's worth remembering that '293 is targeting the challenging r/r AML market. While there are solid treatment options available as front-line therapies, some patients cannot tolerate them, some do not respond, and others ultimately see their disease mutate around the treatment and become non-responsive/relapsing. Keep this in mind when comparing response rates to other drugs in the space (make sure it's an "apples to apples" comparison). Another Chance For Luxeptinib Aptose's prior lead drug, luxeptinib, still factors significantly into the company's clinical plans today. While the drug showed exciting pre-clinical attributes, clinical results today have not matched that potential. It would seem that the pharmacokinetics of the drug are at least partly to blame, and the company is hoping that a reformulated version of the drug (known as "G3") can lead to patients getting consistent therapeutic doses that produce clinical results. Clinical trial work is underway now, with patients getting G3 at 50mg, 100mg, and 200mg doses and the 50mg dose of G3 demonstrating 200x the exposure level of a 150mg dose of G1. Assuming that the pharmacokinetics and pharmacodynamics (PK and PD) studies merit further development, Aptose should be able to start dose escalation studies of the new formulation in the first half of 2023 in patients with r/r B-cell or r/r AML disease.
Seeking Alpha • Feb 02

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech. A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, but it's a "show me" story. Recently-acquired '239 looks like an interesting asset for AML, with promising Phase 1 response rates, but it's still early in the development cycle. Between '239 and luxeptinib there is still potential in Aptose's pipeline, but it will take real evidence of clinical efficacy to rebuild sentiment.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de William Rice en comparación con los beneficios de Aptose Biosciences?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$28m

Dec 31 2025US$1mUS$677k

-US$25m

Sep 30 2025n/an/a

-US$19m

Jun 30 2025n/an/a

-US$21m

Mar 31 2025n/an/a

-US$21m

Dec 31 2024US$1mUS$647k

-US$25m

Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$47m

Dec 31 2023US$925kUS$623k

-US$51m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$48m

Mar 31 2023n/an/a

-US$44m

Dec 31 2022US$2mUS$599k

-US$42m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

-US$58m

Mar 31 2022n/an/a

-US$61m

Dec 31 2021US$2mUS$582k

-US$65m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$12mUS$582k

-US$55m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$562k

-US$26m

Compensación vs. Mercado: La compensación total de William($USD1.08M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD638.05K).

Compensación vs. Ingresos: La compensación de William ha sido consistente con los resultados de la empresa en el último año.

CEO

William Rice (66 yo)

12.6yrs
Permanencia
US$1,077,641
Compensación

Dr. William G. Rice, Ph D., had served as an Independent Director of Oncolytics Biotech Inc. since June 08, 2015 until June 30, 2021. He has been the Chief Executive Officer and President of Aptose Bioscie...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
William Rice
Chairman12.6yrsUS$1.08m0.18%
$ 7.6k
Fletcher Payne
Senior VP3.9yrsUS$710.58k0.0096%
$ 412.6
Rafael Bejar
Senior VP & Chief Medical Officer6.3yrsUS$754.62k0.0096%
$ 412.6
6.3yrs
Permanencia media
62yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de APTO.F es experimentado (6.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
William Rice
Chairman12.6yrsUS$1.08m0.18%
$ 7.6k
Mark Vincent
Independent Director18.7yrsUS$95.00k0.00055%
$ 23.7
Bernd Seizinger
Independent Director3.7yrsUS$103.50k0.022%
$ 956.9
Denis Burger
Lead Independent Director18.7yrsUS$128.50k0.0019%
$ 81.1
Stephen Howell
Member of Scientific Advisory Boardno datasin datossin datos
Daniel Von Hoff
Member of Scientific Advisory Boardno datasin datossin datos
Erich Platzer
Independent Director11.4yrsUS$90.00k0.044%
$ 1.9k
Warren Whitehead
Independent Director15.1yrsUS$80.00k0.0013%
$ 55.7
Brian Druker
Chairman of Scientific Advisory Board12.6yrssin datossin datos
Michael Andreeff
Member of Scientific Advisory Board11.2yrssin datossin datos
12.6yrs
Permanencia media
73yo
Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de APTO.F son experimentados ( 12.6 años antigüedad media).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/21 16:09
Precio de las acciones al final del día2026/05/21 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Aptose Biosciences Inc. está cubierta por 9 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Matthew VeneziaAlliance Global Partners
Dylan DupuisB. Riley Securities, Inc.
John NewmanCanaccord Genuity